Literature DB >> 15194546

Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab.

Holger Schulz, Hendrik Pels, Ingo Schmidt-Wolf, Ulrich Zeelen, Ulrich Germing, Andreas Engert.   

Abstract

Most patients with primary central nervous system (CNS) lymphoma or systemic non-Hodgkin's lymphoma (NHL) involving the CNS relapse after an initial response to treatment, often presenting with leptomeningeal disease. Since the majority of these lymphomas are B-cell neoplasms expressing the CD20 surface antigen treatment with the chimeric monoclonal antibody (Mab) rituximab might be a new therapeutic option. Here, we report on 6 patients with relapsed CNS B-cell lymphoma who were treated with intraventricular or intrathecal applications of rituximab. One of these cases has already been reported.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15194546

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  34 in total

Review 1.  Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.

Authors:  Ankit I Mehta; Adam M Brufsky; John H Sampson
Journal:  Cancer Treat Rev       Date:  2012-06-22       Impact factor: 12.111

2.  Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma.

Authors:  Giovanni Antonini; Maria Cristina Cox; Enrico Montefusco; Antonella Ferrari; Esmeralda Conte; Stefania Morino; Pamela Latino; Guido Trasimeni; Bruno Monarca
Journal:  J Neurooncol       Date:  2006-08-26       Impact factor: 4.130

Review 3.  Management of primary intraocular lymphoma.

Authors:  Stella K Kim; Chi-Chao Chan; Dana J Wallace
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

4.  High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder.

Authors:  A Patrick; A Wee; A Hedderman; D Wilson; J Weiss; M Govani
Journal:  J Neurooncol       Date:  2010-09-26       Impact factor: 4.130

5.  Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma.

Authors:  Roy E Strowd; Inas A Abuali; Stuart A Grossman
Journal:  CNS Oncol       Date:  2015-04-23

6.  Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus.

Authors:  John H Beigel; Jeffrey L Nordstrom; Stanley R Pillemer; Cory Roncal; D Ronald Goldwater; Hua Li; P Chris Holland; Syd Johnson; Kathryn Stein; Scott Koenig
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

7.  Two-year-old female with EBV-positive diffuse large B-cell lymphoma and subsequent CNS involvement with neurolymphomatosis.

Authors:  Kari L Bjornard; Vasiliki Leventaki; Kim E Nichols; John T Sandlund; Susan Prockop; Matthew J Ehrhardt
Journal:  Pediatr Blood Cancer       Date:  2018-08-27       Impact factor: 3.167

8.  Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.

Authors:  Klaus Lehmann-Horn; Helena C Kronsbein; Martin S Weber
Journal:  Ther Adv Neurol Disord       Date:  2013-05       Impact factor: 6.570

9.  Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model.

Authors:  John D Morrey; Venkatraman Siddharthan; Aaron L Olsen; Hong Wang; Justin G Julander; Jeffery O Hall; Hua Li; Jeffrey L Nordstrom; Scott Koenig; Syd Johnson; Michael S Diamond
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

10.  Rituximab in the treatment of non-Hodgkin's lymphoma.

Authors:  Beate Hauptrock; Georg Hess
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.